Key Highlights

  • 9.44% is the indicated pre-market decline for Bone Biologics Corp (NASDAQ:BBLG) on November 18, 2026, to USD 0.2801 from a calculated prior close of USD 0.3093, a calculated move of -USD 0.0292 per share.
  • 6.1 million is the USD cash position reported by Bone Biologics Corp (NASDAQ:BBLG), which the company expects to fund operations through the second quarter of 2027 against estimated annual operating expenses of about USD 6 million.
  • 111 days remain, on a calculated basis, from November 18, 2026 to March 9, 2027, when the 180-day Nasdaq bid price compliance period ends for Bone Biologics Corp (NASDAQ:BBLG), whose indicated price is far below USD 1.00.
  • 2027 is the year in which a July 2026 private Placement stops restricting variable rate transactions and at-the-market use for Bone Biologics Corp (NASDAQ:BBLG), a constraint on financing flexibility until July 2027 without purchaser consent.

What Moved Bone Biologics Corp (NASDAQ:BBLG) in Pre-Market Trading on November 18, 2026 (-USD 0.0292, -9.44%)

The indicated pre-market price of Bone Biologics Corp (NASDAQ:BBLG) on November 18, 2026 is USD 0.2801, a pre-market move of -9.44% ahead of the 9:30 a.m. ET open. On a calculated basis, the prior close from the November 17, 2026 regular session was USD 0.3093 (USD 0.2801 divided by 0.9056), so the calculated USD move is -USD 0.0292 (price minus prior close). The indicated price equals 28.01% of the USD 1.00 minimum bid level, a calculated shortfall of USD 0.7199 per share, or a calculated 3.57 times gain needed to reach it.

The Rationale: No Identified Catalyst, With a Nasdaq Bid Deadline Backdrop for Bone Biologics Corp (NASDAQ:BBLG)

No catalyst for the pre-market move was identified in published coverage. As general context, a low-priced, pre-revenue medical technology stock can slip before the open on thin liquidity, continued selling pressure and concern over a pending listing deadline, none presented as the confirmed cause. The company is running a NELL-1/DBM spinal fusion pilot study that is enrolling in Australia, with FDA alignment on the study design for potential U.S. pivotal trials. Reverse stock splits also require purchaser consent under the July 2026 private placement terms.

Valuation, Liquidity and Risks for Bone Biologics Corp (NASDAQ:BBLG)

Cash of USD 6.1 million against estimated annual operating expenses of about USD 6 million implies, on a calculated basis, 1.02 times annual spending (about USD 0.5 million per month), and the company points to a runway through the second quarter of 2027. Substantial doubt about the ability to continue as a Going Concern persists, according to the filings. Nasdaq issued a bid price deficiency notice, the 180-day compliance period expires March 9, 2027, a calculated 111 days from today, and prior reverse splits did not sustain a USD 1.00 bid. Dilution, trial delays, financing limits and possible delisting are central risks.

Where Things Stand

Bone Biologics Corp (NASDAQ:BBLG) is indicated at USD 0.2801 in pre-market trading on November 18, 2026, down 9.44% from a calculated prior close of USD 0.3093. No specific catalyst was identified in published coverage. The company is pre-revenue, holds USD 6.1 million of cash against about USD 6 million of estimated annual operating expenses, and faces a March 9, 2027 Nasdaq bid price compliance deadline. Going-concern language, financing restrictions through July 2027 and the pending NELL-1/DBM pilot study in Australia define the risk and opportunity set. Indications can change at the 9:30 a.m. ET open, and this is not Investment advice.